Alnylam Pharmaceuticals, Inc.
$ALNY
Public valuation for Alnylam Pharmaceuticals, Inc. (ALNY). Fair value, signal, and key metrics — no sign-in required.
Current Price
$246.74
31% Undervalued
Fair Value Estimate
$324
🏛️
Mature Growth
Profitable company with steady growth
Analyst Consensus
Target: $371.35
51% higher than current
Key Metrics
Market Cap
$33.0B
Forward P/E
33.3x
Operating Margin
17.9%
Revenue Growth
81.3%
PEG Ratio
0.66
Get free watchlist alerts
Join the waitlist for valuation updates on $ALNY and the rest of your watchlist.
Join the waitlistJoin the waitlist
Stay on this page to join — no sign-in required.